Sophiris Bio (Sophiris Bio) Margin of Safety % (DCF FCF Based) : N/A (As of May. 05, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Sophiris Bio Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Sophiris Bio's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

Competitive Comparison of Sophiris Bio's Margin of Safety % (DCF FCF Based)

For the Biotechnology subindustry, Sophiris Bio's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sophiris Bio's Margin of Safety % (DCF FCF Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sophiris Bio's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Sophiris Bio's Margin of Safety % (DCF FCF Based) falls into.

Sophiris Bio Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Sophiris Bio's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Sophiris Bio (Sophiris Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sophiris Bio Inc (OTCPK:SPHS) » Definitions » Margin of Safety % (DCF FCF Based)

Comparable Companies

Traded in Other Exchanges

N/A

Address

1258 Prospect Street, La Jolla, CA, USA, 92037

Website

http://www.sophirisbio.com

Sophiris Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of products for the treatment of urological diseases. The company's product portfolio includes topsalysin (PRX302), for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. Topsalysin is a genetically modified recombinant protein which is selectively activated by enzymatically active prostate-specific antigen (PSA), which is only present in the prostate, leading to localized cell death and tissue disruption without damage to neighboring tissue and nerves. Geographically all the operations of the company are functioned in the United States.

Executives

Randall E Woods	director, officer: President & Chief Exec Officer	C/O ARENA PHARMACEUTICALS, INC. 6166 NANCY RIDGE DRIVE SAN DIEGO CA 92121
Lars Ekman	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
James L Heppell	director
Gerald T Proehl	director
John Geltosky	director	685 ROUTE 202/206, BRIDGEWATER NJ 08807
Joseph L Turner	director	10505 ROSELLE STREET, SAN DIEGO CA 92121
Joseph Lewis	10 percent owner	PO BOX N7776, LYFORD BAHAMAS
Boxer Asset Management Inc.	10 percent owner	CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Boxer Capital, Llc	10 percent owner	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Mva Investors, Llc	10 percent owner	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
William R Rohn	director	PO BOX 676367, RANCHO SANTA FE CA 92067